Wilfried Eberhardt

38.4k total citations · 3 hit papers
239 papers, 7.6k citations indexed

About

Wilfried Eberhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wilfried Eberhardt has authored 239 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Pulmonary and Respiratory Medicine, 140 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Wilfried Eberhardt's work include Lung Cancer Treatments and Mutations (141 papers), Lung Cancer Diagnosis and Treatment (84 papers) and Lung Cancer Research Studies (64 papers). Wilfried Eberhardt is often cited by papers focused on Lung Cancer Treatments and Mutations (141 papers), Lung Cancer Diagnosis and Treatment (84 papers) and Lung Cancer Research Studies (64 papers). Wilfried Eberhardt collaborates with scholars based in Germany, United States and United Kingdom. Wilfried Eberhardt's co-authors include Georgios Stamatis, Martin Stuschke, Filippo de Marinis, Robert Pirker, Joachim von Pawel, Christoph Pöttgen, Kenneth J. O’Byrne, Maciej Krzakowski, Rodryg Ramlau and Keunchil Park and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Wilfried Eberhardt

224 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Jose R. Pereira et al. profile →
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013 367 citations Wilfried Eberhardt et al. profile →

Peers

Countries citing papers authored by Wilfried Eberhardt

Since Specialization

Citations

This map shows the geographic impact of Wilfried Eberhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Eberhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Eberhardt more than expected).

Fields of papers citing papers by Wilfried Eberhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilfried Eberhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Eberhardt. The network helps show where Wilfried Eberhardt may publish in the future.

Co-authorship network of co-authors of Wilfried Eberhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Wilfried Eberhardt. A scholar is included among the top collaborators of Wilfried Eberhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilfried Eberhardt. Wilfried Eberhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer 2024 ·Journal of Thoracic Oncology ·Kwun M. Fong, Adam Rosenthal, Dorothy J. Giroux, Katherine K. Nishimura, Jeremy J. Erasmus, Yolande Lievens, Mirella Marino, Edith M. Marom, Paul Martin Putora, Navneet Singh, Francisco Suárez, Ramón Rami–Porta, Frank C. Detterbeck, Wilfried Eberhardt, Hisao Asamura	23
2	Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315) 2024 ·International Journal of Cancer ·Martin Sebastian, Wilfried Eberhardt, (unknown), Steffen Dörfel, (unknown), (unknown), Christoph Losem, Martina Jänicke, (unknown), Stefan Zacharias, (unknown), A. Hipper, (unknown), Annalen Bleckmann, (unknown), (unknown), Christian Grah, Annette Müller, Frank Griesinger, Michael Thomas, (unknown)	0
3	Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease 2024 ·Cancers ·Maja Guberina, Christoph Pöttgen, Nika Guberina, (unknown), Marcel Wiesweg, (unknown), Martin Metzenmacher, Clemens Aigner, Servet Bölükbas, Thomas Gauler, Wilfried Eberhardt, Michael Forsting, Ken Herrmann, Dirk Theegarten, Kaid Darwiche, Verena Jendrossek, Martin Stuschke, Martin Schüler	3
4	The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need? 2024 ·Cancers ·(unknown), (unknown), (unknown), Martin Metzenmacher, Wilfried Eberhardt, Ken Herrmann, Hubertus Hautzel, Clemens Aigner, Till Plönes	1
5	Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment 2021 ·European Journal of Cardio-Thoracic Surgery ·Georgios Stamatis, Stefanie Müller, Gerhard Weinreich, (unknown), Wilfried Eberhardt, Christoph Pöttgen, Clemens Aigner	6
6	Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms – Ein Experten-Konsensuspapier 2021 ·Pneumologie ·Clemens Aigner, Thomas Brüning, Wilfried Eberhardt, Martin Härter, (unknown), Martin Metzenmacher, Rajiv Shah, Christian Taube, Michael Thomas	1
7	DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients 2021 ·European Journal of Cancer ·(unknown), Kaid Darwiche, Michał Seweryn, Vedat Yildiz, Peter J. Kneuertz, Wilfried Eberhardt, Stephan Eisenmann, Stefan Welter, (unknown), Maciej Pietrzak, Marcel Wiesweg, Till Ploenes, Thomas Hager, Kai He, Lutz Freitag, Clemens Aigner, Christian Taube, Filiz Öezkan	24
8	Neoadjuvant and adjuvant end-points in health technology assessment in oncology 2021 ·European Journal of Cancer ·Nadia Harbeck, Andreas Schneeweiß, Peter Thuss‐Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried Eberhardt, Jens Peter Klußmann, Barbara Wollenberg, Marc‐Oliver Grimm, Thomas Zander, Diana Lüftner	9
9	Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context 2020 ·European Journal of Cancer ·Marcel Wiesweg, Fabian Mairinger, Henning Reis, Moritz Goetz, Jens Kollmeier, Daniel Misch, Susann Stephan-Falkenau, Thomas Mairinger, Robert Walter, Thomas Hager, Martin Metzenmacher, Wilfried Eberhardt, (unknown), Johannes Köster, Martin Stuschke, Clemens Aigner, Kaid Darwiche, Kurt Werner Schmid, Sven Rahmann, Martin Schüler	37
10	Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve 2020 ·European Journal of Cancer ·Nika Guberina, Christoph Pöttgen, Martin Schüler, Maja Guberina, Georgios Stamatis, Till Plönes, (unknown), Martin Metzenmacher, Dirk Theegarten, Thomas Gauler, Karl‐Heinz Jöckel, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Wilfried Eberhardt	4
11	Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma 2020 ·Scientific Reports ·(unknown), (unknown), Robert Walter, (unknown), (unknown), (unknown), Balázs Hegedűs, Thomas Hager, Thomas Herold, Wilfried Eberhardt, Jeremias Wohlschlaeger, Clemens Aigner, Ágnes Bánkfalvi, Kurt Werner Schmid, Fabian Mairinger	17
12	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer 2020 ·Lung Cancer ·(unknown), (unknown), Saskia Ting, Henning Reis, Martin Metzenmacher, Wilfried Eberhardt, (unknown), Thomas Herold, Clemens Aigner, Kaid Darwiche, Martin Stuschke, Hans‐Ulrich Schildhaus, Martin Schüler, Marcel Wiesweg	9
13	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation 2019 ·Lung Cancer ·Marcel Wiesweg, Thomas Herold, Martin Metzenmacher, Wilfried Eberhardt, Henning Reis, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Ken Herrmann, Felix Nensa, Hans‐Ulrich Schildhaus, Martin Schüler	4
14	EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study 2015 ·Cancer Epidemiology Biomarkers & Prevention ·Wolfgang Schuette, Peter Schirmacher, Wilfried Eberhardt, (unknown), J.-Matthias Graf von der Schulenburg, J. Mezger, Christian Schumann, Monika Serke, (unknown), Manfred Dietel, Michael Thomas	29
15	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations 2014 ·Clinical Cancer Research ·Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García, Véronique Dièras, Jan H.M. Schellens, Jean‐Philippe Spano, Mark R. Middleton, Emiliano Calvo, L. Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber‐Bodéré, Jean Tessier, Wilfried Eberhardt, Michel Pâques, Ernesto Guarin, Valérie Méresse, Jean‐Charles Soria	59
16	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, (unknown), (unknown), Jan H.M. Schellens, Wilfried Eberhardt	55
17	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study breakdown → 2011 ·The Lancet Oncology ·Robert Pirker, Jose R. Pereira, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo de Marinis, Wilfried Eberhardt, Luis Paz‐Ares, Stephan Störkel, (unknown), Anja von Heydebreck, Ilhan Celik, Kenneth J. O’Byrne	453
18	Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study 2009 ·Journal of Clinical Oncology ·Ronald B. Natale, David Bodkin, Ramaswamy Govindan, Bethany Sleckman, Naiyer A. Rizvi, (unknown), Paul Germonpré, Wilfried Eberhardt, Paul K. Stockman, Sarah J. Kennedy, Malcolm Ranson	194
19	Abstracts 2003 ·British Journal of Cancer ·Ahmad Awada, Jean Klášterský, (unknown), Christian Stoll, (unknown), (unknown), S. Korfee, Gerald Antoch, Thomas Gauler, Wilfried Eberhardt, Anna Kowalczyk, Rafał Dziadziuszko, Ewa Szutowicz-Zielińska, A. Badzio, Jacek Jassem	1
20	Mono clonal antibodies for the specific detection and quantitation of dna components structurally modified by alkylating carcinogens 1981 ·Journal of Cancer Research and Clinical Oncology ·J Adamkiewicz, Wilfried Eberhardt, (unknown), (unknown), Manfred F. Rajewsky	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact